To include your compound in the COVID-19 Resource Center, submit it here.

Werewolf debuts with $56M to develop tumor-activated biologics

Emerging from stealth with a $56 million series A round, Werewolf Therapeutics is aiming to increase the therapeutic window of cytokines and immuno-stimulatory antibodies by masking their activity until they reach the tumor

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers